{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:40Z","timestamp":1761895060657,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.014","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T04:51:45Z","timestamp":1270011105000},"page":"S11-S14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S1","title":["Novel Agents in Development for Peripheral T-Cell Lymphoma"],"prefix":"10.1053","volume":"47","author":[{"given":"Owen A.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.014_bib1","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib3","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V112.11.1567.1567","article-title":"Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) [abstr 1567]","volume":"112","author":"Piekarz","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood.V114.22.1674.1674","article-title":"Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase I results [abstr 1674]","volume":"114","author":"Horwitz","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib9","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib11","doi-asserted-by":"crossref","first-page":"454s","DOI":"10.1200\/jco.2009.27.15_suppl.8584","article-title":"Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) [abstr 8584]","volume":"27","author":"Paoluzzi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib12","doi-asserted-by":"crossref","first-page":"452s","DOI":"10.1200\/jco.2009.27.15_suppl.8574","article-title":"ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) [abstr 8574]","volume":"27","author":"Wilson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V112.11.2108.2108","article-title":"Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies [abstr 2108]","volume":"112","author":"Wilson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib14","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib15","doi-asserted-by":"crossref","first-page":"439s","DOI":"10.1200\/jco.2009.27.15_suppl.8524","article-title":"Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases [abstr 8524]","volume":"27","author":"Dueck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib16","first-page":"3328","article-title":"[Purine nucleoside phosphorylase (PNP) deficiency]","volume":"54","author":"Sakiyama","year":"1996","journal-title":"Nippon Rinsho"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib17","doi-asserted-by":"crossref","first-page":"524a","DOI":"10.1182\/blood.V108.11.1851.1851","article-title":"Forodesine IV (Bcx-1777) is clinically active in relapsed\/refractory T-cell leukemia: results of a phase II study (interim report) [abstr 1851]","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/bjc.1991.423","article-title":"Deoxycoformycin in the treatment of mature T-cell leukaemias","volume":"64","author":"Dearden","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib20","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2579.2579","article-title":"First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma","volume":"110","author":"Reiman","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.014_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:00Z","timestamp":1758522000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":23,"alternative-id":["S0037196310000156"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.014","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Agents in Development for Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}